Knockout News and Research

RSS

Brain tumors exploit body's daily rhythms to fuel growth

Scientists explore how daily glucocorticoid signaling influences glioblastoma growth and synchronizes its circadian rhythms with the host.

18 Dec 2024

Researchers gain new insights into the molecular changes leading to Rett syndrome

Researchers at Baylor College of Medicine, Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital and collaborating institutions have gained new insights into the molecular changes leading to Rett syndrome, a severe neurological disorder caused by mutations in the MeCP2 gene encoding methyl-CpG binding protein 2 (MeCP2).

16 Dec 2024

FunMap reveals new insights into cancer-associated genes and proteins

Large-scale protein and gene profiling have massively expanded the landscape of cancer-associated proteins and gene mutations, but it has been difficult to discern whether they play an active role in the disease or are innocent bystanders.

11 Dec 2024

Extracellular vesicle DNA regulates immune responses and suppresses liver metastasis

The study highlights how EV-DNA packaging influences immune responses and its promise as a biomarker for assessing colorectal cancer metastasis risk.

6 Dec 2024

SRF awards $230,000 grant to advance research on SYNGAP1-Related Disorders

The SynGAP Research Fund (SRF) has awarded a $230,000 grant to The Jackson Laboratory Rare Disease Translational Center to characterize a mouse model for SYNGAP1-Related Disorders, (SRD), a severe neurodevelopmental disorder marked by seizures, intellectual disabilities, and motor and behavioral challenges.

4 Dec 2024

Fas-p53 pathway drives metabolic dysfunction and obesity-linked insulin resistance

Researchers unveil Fas-p53 axis as a key regulator in adipocyte metabolism, linking it to obesity and insulin sensitivity through energy expenditure and inflammation pathways.

3 Dec 2024

Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a next-generation biopharmaceutical company spearheading innovation of multispecific biologics in ophthalmic therapies

From Asimov 25 Nov 2024

Spermidine regulates RIPK1 to combat diabetes and vascular damage

Researchers reveal that spermidine-mediated acetylhypusination of RIPK1 suppresses necroptosis and insulin resistance, offering potential therapeutic strategies for type 2 diabetes.

18 Nov 2024

Vitamin D receptor activation slows cell overgrowth in pulmonary hypertension

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in pulmonary arterial smooth muscle cells, potentially reducing disease severity in pulmonary arterial hypertension (PAH).

12 Nov 2024

Key reason why some cancers do not respond to immunotherapy identified

Research reveals SLC13A3's role in tumor cell survival and immune therapy resistance, highlighting its potential as a target for improved cancer treatments.

12 Nov 2024

Mitochondria’s division of labor sheds light on how cancer cells survive harsh conditions

Research shows mitochondria form distinct subpopulations under nutrient stress, revealing survival mechanisms in cancer cells and potential therapeutic targets.

12 Nov 2024

New genetic model offers insights into breast cancer metastasis

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and where cancer metastasizes.

11 Nov 2024

Exploring mouse models for studying liver fibrosis regression

Liver fibrosis is a progressive and potentially reversible condition that results from chronic liver damage, which can be caused by a variety of factors, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol abuse, and viral hepatitis.

8 Nov 2024

New study identifies potential treatment for tauopathies using carbonic anhydrase inhibitors

Carbonic anhydrase inhibitors show potential in reducing tau protein buildup, offering new therapeutic avenues for neurodegenerative diseases like tauopathies.

4 Nov 2024

Critical protein linked to spillover potential of animal viruses

Scientists investigating animal viruses with potential to infect humans have identified a critical protein that could enable spillover of a family of organisms called arteriviruses.

1 Nov 2024

Taurine supplementation linked to reduced atherosclerotic plaque development

Previous studies suggest that taurine supplementation may attenuate atherosclerosis by reducing lipid levels. However, energy drinks containing taurine have been shown to increase blood pressure, a key risk factor for atherosclerosis. Thus, the role of taurine in atherosclerosis remains controversial.

26 Oct 2024

Persistent activation of DNA damage response in the liver after MASLD reversal

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more advanced form, metabolic dysfunction-associated steatohepatitis, have emerged as the most prevalent liver diseases worldwide.

25 Oct 2024

Senolytic agents show promise in mouse model of pelvic organ prolapse

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 19 on September 26, 2024, entitled, "Use of the senolytics dasatinib and quercetin for prevention of pelvic organ prolapse in a mouse animal model."

22 Oct 2024

New nanoparticle system fights obesity

Researchers have unveiled a novel approach to tackle obesity by targeting fat absorption in the small intestine. The cutting-edge nanoparticle system, engineered to deliver therapeutic molecules directly to the digestive tract, has shown significant potential to prevent diet-induced obesity.

14 Oct 2024

When CDK12/13 stalls, healthy prostate cells take a malignant turn

CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted therapies.

7 Oct 2024